Cañellas AR, Gols AR, Izquierdo JR et al (2007) Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 49:393–409. https://doi.org/10.1007/s00234-007-0216-2

Article  PubMed  Google Scholar 

Costello F (2022) Neuromyelitis optica spectrum disorders. Contin Lifelong Learn Neurol 28:1131–1170. https://doi.org/10.1212/CON.0000000000001168

Article  Google Scholar 

Longbrake E (2022) Myelin oligodendrocyte glycoprotein-associated disorders. Contin Lifelong Learn Neurol 28:1171–1193. https://doi.org/10.1212/CON.0000000000001127

Article  Google Scholar 

Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20:762–772. https://doi.org/10.1016/S1474-4422(21)00218-0

Article  CAS  PubMed  Google Scholar 

Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. https://doi.org/10.1016/S1474-4422(22)00431-8

Article  PubMed  Google Scholar 

Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. https://doi.org/10.1212/WNL.0000000000001729

Article  PubMed  PubMed Central  Google Scholar 

Bennett JL, Costello F, Chen JJ et al (2023) Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 22:89–100. https://doi.org/10.1016/S1474-4422(22)00187-9

Article  CAS  PubMed  Google Scholar 

Chen JJ, Tobin WO, Majed M et al (2018) Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4–IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol 136:419. https://doi.org/10.1001/jamaophthalmol.2017.6757

Article  PubMed  PubMed Central  Google Scholar 

Chen JJ, Flanagan EP, Bhatti MT, et al (2022) Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. Mult Scler Relat Disord 68:104237. https://doi.org/10.1016/j.msard.2022.104237

Vosoughi AR, Muccilli A, Schneider R, et al (2022) Recovery of Vision in Myelin Oligodendrocyte Glycoprotein–IgG Optic Neuritis Without Treatment: A Case Series. J Neuro-Ophthalmology Publish Ah:3–5. https://doi.org/10.1097/WNO.0000000000001583

Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60–67. https://doi.org/10.1016/S1474-4422(20)30392-6

Article  CAS  PubMed  Google Scholar 

Sechi E, Krecke KN, Messina SA et al (2021) Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology 97:e1097–e1109. https://doi.org/10.1212/WNL.0000000000012467

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127. https://doi.org/10.1002/ana.1032

Article  CAS  PubMed  Google Scholar 

Sechi E, Cacciaguerra L, Chen JJ, et al (2022) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 13:885218. https://doi.org/10.3389/fneur.2022.885218

Beck RW, Cleary PA, Anderson MM et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581–588. https://doi.org/10.1056/nejm199202273260901

Article  CAS  PubMed  Google Scholar 

Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8–15. https://doi.org/10.1016/j.ajo.2018.07.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaitán MI, Paday Formenti ME, Calandri I, et al (2022) The central vein sign is present in most infratentorial multiple sclerosis plaques. Mult Scler Relat Disord 58:103484. https://doi.org/10.1016/j.msard.2021.103484

Costello F, Scott JN (2019) Imaging in Neuro-ophthalmology. Contin Lifelong Learn Neurol 25:1438–1490. https://doi.org/10.1212/CON.0000000000000783

Article  Google Scholar 

Myers KA, Nikolic A, Romanchuk K et al (2017) Optic neuropathy in the context of leukemia or lymphoma: diagnostic approach to a neuro-oncologic emergency. Neuro-Oncology Pract 4:60–66. https://doi.org/10.1093/nop/npw006

Article  Google Scholar 

Abrams RMC, Safavi F, Tuhrim S et al (2021) MRI negative myelopathy post mild SARS-CoV-2 infection: vasculopathy or inflammatory myelitis? J Neurovirol 27:650–655. https://doi.org/10.1007/s13365-021-00986-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tobin WO, Guo Y, Krecke KN et al (2017) Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 140:2415–2425. https://doi.org/10.1093/brain/awx200

Article  PubMed  Google Scholar 

Guo J, Bu Y, Liu W (2022) Case Report: A Case With MOGAD and Anti-NMDAR Encephalitis Overlapping Syndrome Mimicing Radiological Characteristics of CLIPPERS. Front Immunol 13:832084. https://doi.org/10.3389/fimmu.2022.832084

Banks SA, Morris PP, Chen JJ et al (2021) Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry 92:384–390. https://doi.org/10.1136/jnnp-2020-325121

Article  Google Scholar 

Pike M (2013) Opsoclonus–myoclonus syndrome. In: Handbook of Clinical Neurology. Elsevier, pp 1209–1211

Stunkel L, Kung NH, Wilson B et al (2018) Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol 136:76. https://doi.org/10.1001/jamaophthalmol.2017.5470

Article  PubMed  Google Scholar 

Kunchok A, Krecke KN, Flanagan EP et al (2020) Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG–associated disorders (MOGAD)? Neurology 94:85–88. https://doi.org/10.1212/WNL.0000000000008786

Article  PubMed  Google Scholar 

Jonathan Maran J, Sharpe C, Carroll S (2023) Journal Pre-proof Paediatric MOG-antibody disease presenting with intracranial hypertension and unilateral vision loss without radiological evidence of optic neuritis. J Neuroimmunol. https://doi.org/10.1016/j.jneuroim.2023.578083

Article  Google Scholar 

Marignier R (2019) Unusual presentations of MOG antibody-associated central nervous system demyelination: expanding the spectrum. Mult Scler J 25:128–129. https://doi.org/10.1177/1352458518804127

Article  Google Scholar 

Valdrighi A, Russ J, Waubant E, et al (2021) Atypical myelin oligodendrocyte glycoprotein antibody disease presenting with isolated elevated intracranial pressure. Neuroimmunol Reports 1:100028. https://doi.org/10.1016/j.nerep.2021.100028

Vosoughi AR, Ling J, Tam KT et al (2021) Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. Br J Ophthalmol 105:1591–1598. https://doi.org/10.1136/bjophthalmol-2020-317267

Article  PubMed  Google Scholar 

Costello F (2014) Inflammatory optic neuropathies. Continuum (Minneap Minn) 20:816–37. https://doi.org/10.1212/01.CON.0000453316.60013.52

Reindl M, Schanda K, Woodhall M, et al (2020) International multicenter examination of MOG antibody assays. Neurol—Neuroimmunol Neuroinflammation 7:e674. https://doi.org/10.1212/NXI.0000000000000674

Sechi E, Buciuc M, Pittock SJ et al (2021) Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 78:741. https://doi.org/10.1001/jamaneurol.2021.0912

Article  PubMed  Google Scholar 

Manzano GS, Salky R, Mateen FJ et al (2022) Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort. Front Neurol 13:1–4. https://doi.org/10.3389/fneur.2022.947630

Article  Google Scholar 

Benard-seguin E, Costello F (2023) Optic neuritis : current challenges in diagnosis and management. 36:10–18. https://doi.org/10.1097/WCO.0000000000001128

Carta S, Cobo Calvo Á, Armangué T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF. Neurology 100:e1095–e1108. https://doi.org/10.1212/WNL.0000000000201662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dinoto A, Sechi E, Flanagan EP et al (2022) Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease. Front Neurol 13:1–13. https://doi.org/10.3389/fneur.2022.866824

Article  Google Scholar 

Pace S, Orrell M, Woodhall M et al (2022) Frequency of MOG-IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry 93:334–335. https://doi.org/10.1136/jnnp-2021-326779

Article  PubMed  Google Scholar 

Kwon YN, Kim B, Kim J-S, et al (2022) Myelin Oligodendrocyte glycoprotein-immunoglobulin G in the CSF. Neurol—Neuroimmunol Neuroinflammation 9:e1095. https://doi.org/10.1212/NXI.0000000000001095

Mariotto S, Gajofatto A, Batzu L et al (2019) Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology 93:e1867–e1872. https://doi.org/10.1212/WNL.0000000000008479

Article  CAS  PubMed  Google Scholar 

Kunchok A, Chen JJ, McKeon A et al (2020) Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients. JAMA Neurol 77:257. https://doi.org/10.1001/jamaneurol.2019.3656

Article  PubMed  Google Scholar 

Lerch M, Bauer A, Reindl M (2023) The Potential pathogenicity of myelin oligodendrocyte glycoprotein antibodies in the optic pathway. J Neuro-Ophthalmology 43:5–16. https://doi.org/10.1097/WNO.0000000000001772

Article  Google Scholar 

Traboulsee A, Simon JH, Stone L et al (2016) Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol 37:394–401. https://doi.org/10.3174/ajnr.A4539

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bacioglu M, Maia LF, Preische O et al (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56–66. https://doi.org/10.1016/j.neuron.2016.05.018

Article  CAS  PubMed  Google Scholar 

Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577–589. https://doi.org/10.1038/s41582-018-0058-z

Article  CAS  PubMed  Google Scholar 

Luo W, Chen Y, Mao S et al (2022) Serum neurofilament light chain in adult and pediatric patients with myelin oligodendrocyte glycoprotein antibody-associated disease: Correlation with relapses and seizures. J Neurochem 160:568–577. https://doi.org/10.1111/jnc.15549

Article  CAS  PubMed  Google Scholar 

Chang X, Huang W, Wang L, et al (2021) Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Front Immunol 12:647618. https://doi.org/10.3389/fimmu.2021.647618

Kim H, Lee E-J, Kim S, et al (2020) Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease. Neurol—Neuroimmunol Neuroinflammation 7:e708. https://doi.org/10.1212/NXI.0000000000000708